Description

Lynparza (Olaparib) 150mg Tablets – 112 Count Imported

Lynparza 150mg Tablets contain olaparib, a targeted cancer therapy classified as a PARP (poly ADP-ribose polymerase) inhibitor. It is used in the treatment of certain types of cancers by blocking DNA repair pathways in cancer cells, leading to tumor cell death while sparing most normal cells.

Each imported pack contains 112 tablets, manufactured to international quality standards.

---

Key Features

• Brand Name: Lynparza

• Active Ingredient: Olaparib 150mg

• Pack Size: 112 tablets per box

• Dosage Form: Oral tablets (film-coated)

• Manufacturer: AstraZeneca

• Imported Medicine: Available in Pakistan through authorized suppliers

---

Uses of Lynparza (Olaparib)

Lynparza is prescribed for the treatment of:

• Ovarian Cancer – maintenance therapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

• Breast Cancer – in patients with BRCA1/2 gene mutations

• Pancreatic Cancer – maintenance treatment for metastatic pancreatic adenocarcinoma with germline BRCA mutations

• Prostate Cancer – for metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene mutations

---

Dosage and Administration

• Typical Dose: 300mg (two 150mg tablets) taken orally twice daily

• Tablets should be swallowed whole, with or without food

• Treatment should continue until disease progression or unacceptable toxicity occurs

• Dose adjustments may be required based on tolerance and side effects
  ⚠️ Always use Lynparza exactly as prescribed by your oncologist.

---

Mechanism of Action

Lynparza works by inhibiting PARP enzymes, which cancer cells rely on to repair damaged DNA. By blocking this repair mechanism, Lynparza causes DNA damage to accumulate, leading to cancer cell death, especially in patients with BRCA1/2 mutations or homologous recombination deficiency (HRD).

---

Benefits of Lynparza Tablets

• Targeted cancer therapy with proven efficacy in BRCA-mutated cancers

• Helps extend progression-free survival in ovarian, breast, pancreatic, and prostate cancers

• Oral tablet form for convenient at-home treatment

• Recognized globally as a leading PARP inhibitor

---

Safety and Side Effects

Common side effects may include:

• Fatigue, nausea, vomiting

• Anemia or low blood counts

• Decreased appetite

• Headache, dizziness

• Gastrointestinal upset (indigestion, diarrhea)

⚠️ Patients should undergo regular blood tests to monitor blood counts and organ function during therapy.

---

Storage Instructions

• Store below 30°C, in the original packaging

• Protect from moisture and direct light

• Keep out of reach of children

---

Summary

Lynparza (Olaparib) 150mg 112 Tablets is an imported, targeted therapy designed for the management of BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By blocking PARP enzymes, Lynparza effectively disrupts DNA repair in cancer cells, slowing disease progression and improving survival outcomes.